Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia

NCT01535053 is registered in ClinicalTrials.gov with GOG Foundation as lead sponsor.

NCT NCT01535053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01535053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Lead sponsor
GOG Foundation
Phase
Phase 3
Overall status
Completed
Start date
June 18, 2012
Completion date
July 17, 2020
Enrollment
57 (actual)
Sites
289

Conditions

As the registry lists them; a condition with its own page is linked.

choriocarcinoma, figo stage i gestational trophoblastic tumor, figo stage ii gestational trophoblastic tumor, figo stage iii gestational trophoblastic tumor, hydatidiform mole